SPARC gets orphan drug designation from USFDA for novel kinase inhibitor

SPARC gets orphan drug designation from USFDA for novel kinase inhibitor The Orphan Drug Act provides economic incentives to encourage the development of drugs for diseases affecting fewer than 2 lakh people in the US, Sun Pharma Advanced Research Company (SPARC) said in a filing to BSE.

No comments:

Post a Comment